MindWalk Holdings (HYFT) Depreciation & Amortization (CF) (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Depreciation & Amortization (CF) of $156363.6 for Q1 2026, down 84.1% year-over-year from $983379.9 in Q1 2025, and up 4.79% quarter-over-quarter from $149222.0 in Q4 2025.
MindWalk Holdings (HYFT) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $156363.6 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 84.1% year-over-year to $156363.6; the TTM figure through Apr 2026 stood at $991159.4 (down 70.92% YoY), while the FY2025 annual figure was $1.4 million, up 9.03% from the prior year.
- Depreciation & Amortization (CF) climbed to $156363.6 in Q1 2026 per HYFT's latest filing, from $149222.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q1 2023 and bottomed at $149222.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $794250.7 across 4 years, with a median of $983379.9 in 2025.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) increased 3.77% — and 2025, when it plunged 85.59%.
- MindWalk Holdings' Depreciation & Amortization (CF) stood at $997829.2 in 2023, then increased by 3.77% to $1.0 million in 2024, then slumped by 85.59% to $149222.0 in 2025, then climbed by 4.79% to $156363.6 in 2026.
- Business Quant data shows HYFT's Depreciation & Amortization (CF) at $156363.6 in Q1 2026, $149222.0 in Q4 2025, and $685573.8 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 156,363.62 |
| Jan 31, 2026 | 156,363.62 |
| Oct 31, 2025 | 149,221.95 |
| Oct 31, 2025 | 149,221.95 |
| Jul 31, 2025 | 685,573.78 |
| Jul 31, 2025 | 685,573.78 |
| Apr 30, 2025 | 370,338.02 |
| Apr 30, 2025 | 370,338.02 |
| Jan 31, 2025 | 983,379.89 |
| Jan 31, 2025 | 983,379.89 |
| Oct 31, 2024 | 1.04 Mn |
| Oct 31, 2024 | 1.04 Mn |
| Jul 31, 2024 | 1.02 Mn |
| Jul 31, 2024 | 1.02 Mn |
| Jan 31, 2024 | 968,295.41 |
| Jan 31, 2024 | 968,295.41 |
| Oct 31, 2023 | 997,829.23 |
| Oct 31, 2023 | 997,829.23 |
| Jul 31, 2023 | 1.12 Mn |
| Jul 31, 2023 | 1.12 Mn |